Under the agreement, Merck will fund ongoing research in the laboratory of Laurie Glimcher, the Irene Heinz given professor of immunology at Harvard School of Public Health, and a professor of medicine at Harvard Medical School, and will be granted a license to certain specific molecules that may arise from this project.
Dr Glimcher’s emerging research sheds new light on the key molecular events that underlie bone formation in adults, yielding insights that open new potential avenues for intervening with therapies designed to treat or prevent osteoporosis.
Isaac Kohlberg, senior associate provost and chief technology development officer at Harvard’s Technology Development Office, said: “This major collaboration reflects our continued dedication to ensuring that our faculty’s leading-edge research advances rapidly into clinical development, and ultimately, medical practice.”